Yifei Wang

Yifei Wang

Auto-generated profile, based on publicly available information

Yifei Wang

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China; Department of Dermatology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
YWYifei Wang
Yifei Wang
CSChen Shen
Chen Shen
DLDanping Liu
Danping Liu
LYLiu Yang
Liu Yang
CHChangzheng Huang
Changzheng Huang
JTJuan Tao
Juan Tao
Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real‐world evidence is still scarce. Thirty‐nine pediatric patients with uncontrolled AD who regularly received dupilumab were included in a single‐center retrospective study. Eight patients (20.5%) were aged 2 to <6 years, fifteen (38.5%) were 6 to <12 years, and sixteen were 12 to <18 years. Changes in clinical AD scores (EASI, SCORAD, P‐NRS, CDLQI, and POEM) at baseline, week 4 (W4), W10, and W16, as well as safety data were collected. At W16, the average EASI values dropped from 29.0 ± 16.2 to 5.1 ± 4.7, and 22 patients (73.3%) achieved 75% improvement in EASI. 16 patients (53.3%) achieved 75% improvement in SCORAD. Significant reduction was also observed in the changes of P‐NRS, CDLQI, and POEM values. Notably, the change of clinical scores was similar among three age subgroups. At W16, the mean percent decreases in EASI for 2 to <6 years, 6 to <12 years, and 12 to 6‐year‐old patients and the injection site reaction in one <6‐year‐old child. Dupilumab exhibited favorable efficacy and safety profile, including the 2 to <6 years old subgroup.

6 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
ZCZhiqiang Chen
Zhiqiang Chen
SWShuaibo Wang
Shuaibo Wang
YWYifei Wang
Yifei Wang
Background: The risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD), especially when receiving treatment with Janus kinase inhibitors (JAKi), has been reported in observational studies. however, the causal relationships between them remain unclear. We aim to explore the causal effects of AD and JAKi on VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods: Two-sample Mendelian randomization (MR) analyses were conducted to examine the causal between genetic susceptibility to AD or JAKi target genes (including JAK1, JAK2, JAK3 and tyrosine kinase 2 [TYK2]) and VTE (encompassing DVT and PE) using summary statistics from genome-wide association studies and eQTLGen project. Inverse variance weighting with random effect method was used as the main analytic approach. Pleiotropy and heterogeneity tests were conducted to assess the robustness of the findings. Results: No significant causal effects were found between AD and the risk of (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.91-1.03, P = .352), DVT (OR: 0.99, 95% CI: 0.89-1.10, P = .789), and PE (OR: 1.06, 95% CI: 0.93-1.20, P = .387). Similarly, there was no causal association between the expression of JAK1, JAK2, JAK3 or TYK2 and VTE, DVT and PE. Conclusion: The MR analysis revealed no genetic causal relationships between either AD or JAKi target genes and VTE. These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.

15 January 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
THTing He
Ting He
YWYifei Wang
Yifei Wang
GYGuoqun Yu
Guoqun Yu
EDEnzhu Dong
Enzhu Dong
CSChen Shen
Chen Shen
JTJuan Tao
Juan Tao

29 December 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
YWYifei Wang
Yifei Wang
ZSZexing Song
Zexing Song
YGYaoying Gao
Yaoying Gao
YYYue Yin
Yue Yin
XAXiangjie An
Xiangjie An
JTJuan Tao
Juan Tao